What is the typical incubation period for malaria. How long does it take for malaria symptoms to appear after infection. Can the malaria incubation period vary between different Plasmodium species. What factors influence the length of the malaria incubation period.

The Basics of Malaria Incubation Periods

Malaria is a potentially life-threatening disease caused by Plasmodium parasites transmitted through the bite of infected female Anopheles mosquitoes. One of the key aspects of malaria infection is its incubation period – the time between being bitten by an infected mosquito and the onset of symptoms.

Understanding the incubation period is crucial for several reasons:

• It helps in early diagnosis and treatment
• It aids in epidemiological studies and outbreak investigations
• It informs travelers about potential risks after returning from malaria-endemic areas

The incubation period for malaria can vary depending on several factors, including the species of Plasmodium causing the infection.

How long is the typical malaria incubation period?

For most Plasmodium species, the typical incubation period ranges from 7 to 30 days. However, this can vary significantly:

• P. falciparum: 6-14 days
• P. vivax and P. ovale: 8-14 days, but can be up to several months
• P. malariae: 7-30 days
• P. knowlesi: as short as 24 hours

Plasmodium falciparum: The Quickest Culprit

Plasmodium falciparum is known for having the shortest incubation period among all Plasmodium species. This rapid development contributes to its potential for causing severe infections.

Why does P. falciparum have a shorter incubation period?

P. falciparum’s shorter incubation period is due to several factors:

1. Rapid replication within red blood cells
2. Ability to infect red blood cells of all ages
3. Higher parasite density in the bloodstream

These characteristics allow P. falciparum to quickly establish a significant infection, leading to earlier symptom onset compared to other Plasmodium species.

Factors Influencing Malaria Incubation Periods

The incubation period of malaria can be influenced by various factors, which can explain the wide range of reported incubation times.

What factors can affect the length of the malaria incubation period?

Several key factors can impact the duration of the malaria incubation period:

• Plasmodium species
• Parasite load (number of parasites transmitted)
• Host immune status
• Genetic factors of both parasite and host
• Use of antimalarial prophylaxis

Understanding these factors can help healthcare providers better assess the risk and timing of malaria infection in individuals with potential exposure.

Unusual Cases: Shorter Incubation Periods

While the typical incubation periods for malaria are well established, there have been reports of unusually short incubation periods, particularly for P. falciparum infections.

Can malaria symptoms appear in less than 5 days after infection?

Recent case reports have documented P. falciparum infections with incubation periods as short as 4 days. These cases are rare but highlight the potential for rapid onset of malaria symptoms in certain circumstances.

Factors that may contribute to such short incubation periods include:

• High parasite load during initial infection
• Highly virulent parasite strains
• Host factors such as immunosuppression

These unusual cases emphasize the importance of considering malaria as a potential diagnosis even when the time since potential exposure is very short.

Long Incubation Periods: The Case of P. vivax and P. ovale

While P. falciparum is known for its short incubation period, P. vivax and P. ovale can have much longer incubation times, sometimes extending to several months or even years.

Why do P. vivax and P. ovale sometimes have extended incubation periods?

The extended incubation periods of P. vivax and P. ovale are due to a unique feature of these parasites: hypnozoites. Hypnozoites are dormant liver stages that can remain inactive for long periods before causing clinical malaria.

Key points about hypnozoites:

• They can remain dormant in the liver for weeks to years
• They are responsible for relapses in P. vivax and P. ovale infections
• They are not affected by most antimalarial drugs, requiring specific treatment

This characteristic of P. vivax and P. ovale makes it crucial to consider these infections even when the last potential exposure was months or years in the past.

Implications for Diagnosis and Treatment

Understanding the variability in malaria incubation periods has important implications for diagnosis and treatment of the disease.

How does knowledge of incubation periods impact malaria management?

Awareness of the range of possible incubation periods affects several aspects of malaria management:

1. Diagnosis: Considering malaria even when symptoms appear shortly after potential exposure or long after leaving an endemic area
2. Treatment: Initiating appropriate treatment based on the likely Plasmodium species
3. Follow-up: Monitoring for potential relapses in P. vivax and P. ovale infections
4. Prevention: Advising travelers on the need for continued vigilance after returning from endemic areas

Healthcare providers must remain alert to the possibility of malaria across a wide range of timeframes following potential exposure.

Malaria Incubation Periods and Public Health

The incubation period of malaria plays a crucial role in public health efforts to control and eliminate the disease.

How do incubation periods influence malaria control strategies?

Understanding malaria incubation periods impacts various aspects of public health strategies:

• Surveillance: Determining the likely time and place of infection in reported cases
• Outbreak investigation: Tracing the source and spread of malaria outbreaks
• Vector control: Timing interventions to interrupt transmission cycles
• Travel recommendations: Advising on prophylaxis duration and post-travel monitoring

By considering the range of possible incubation periods, public health officials can more effectively target their interventions and resources in the fight against malaria.

Future Research and Challenges

While our understanding of malaria incubation periods has grown, there are still areas that require further research and present ongoing challenges.

What are the key areas for future research on malaria incubation periods?

Several important research directions could enhance our knowledge of malaria incubation periods:

1. Genetic factors: Investigating host and parasite genetic elements that influence incubation time
2. Climate change: Studying how changing environmental conditions might affect parasite development and incubation periods
3. Drug resistance: Examining how emerging drug resistance might impact incubation periods and disease progression
4. Improved diagnostics: Developing methods to detect malaria infections during the incubation period

Addressing these research areas could lead to improved strategies for malaria prevention, diagnosis, and treatment, ultimately contributing to global efforts to control and eliminate the disease.

In conclusion, the incubation period of malaria is a critical aspect of the disease that impacts diagnosis, treatment, and public health strategies. While typical ranges are well-established, unusual cases highlight the need for continued vigilance and research. As our understanding of the factors influencing incubation periods grows, we can hope to develop more effective approaches to combating this persistent global health threat.

Malaria

Malaria

• All topics »
• A
• B
• C
• D
• E
• F
• G
• H
• I
• J
• K
• L
• M
• N
• O
• P
• Q
• R
• S
• T
• U
• V
• W
• X
• Y
• Z
• Resources »
  • Fact sheets
  • Facts in pictures
  • Multimedia
  • Publications
  • Questions & answers
  • Tools and toolkits
• Popular »
  • Air pollution
  • Coronavirus disease (COVID-19)
  • Hepatitis
  • Monkeypox
• All countries »
• A
• B
• C
• D
• E
• F
• G
• H
• I
• J
• K
• L
• M
• N
• O
• P
• Q
• R
• S
• T
• U
• V
• W
• X
• Y
• Z
• Regions »
  • Africa
  • Americas
  • South-East Asia
  • Europe
  • Eastern Mediterranean
  • Western Pacific
• WHO in countries »
  • Statistics
  • Cooperation strategies
  • Ukraine emergency
• All news »
  • News releases
  • Statements
  • Campaigns
  • Commentaries
  • Events
  • Feature stories
  • Speeches
  • Spotlights
  • Newsletters
  • Photo library
  • Media distribution list
• Headlines »
• Focus on »
  • Afghanistan crisis
  • COVID-19 pandemic
  • Northern Ethiopia crisis
  • Syria crisis
  • Ukraine emergency
  • Monkeypox outbreak
  • Greater Horn of Africa crisis
• Latest »
  • Disease Outbreak News
  • Travel advice
  • Situation reports
  • Weekly Epidemiological Record
• WHO in emergencies »
  • Surveillance
  • Research
  • Funding
  • Partners
  • Operations
  • Independent Oversight and Advisory Committee
  • WHO’s Health Emergency Appeal 2023
• Data at WHO »
  • Global Health Estimates
  • Health SDGs
  • Mortality Database
  • Data collections
• Dashboards »
  • COVID-19 Dashboard
  • Triple Billion Dashboard
  • Health Inequality Monitor
• Highlights »
  • Global Health Observatory
  • SCORE
  • Insights and visualizations
  • Data collection tools
• Reports »
  • World Health Statistics 2022
  • COVID excess deaths
  • DDI IN FOCUS: 2022
• About WHO »
  • People
  • Teams
  • Structure
  • Partnerships and collaboration
  • Collaborating centres
  • Networks, committees and advisory groups
  • Transformation
• Our Work »
  • General Programme of Work
  • WHO Academy
  • Activities
  • Initiatives
• Funding »
  • Investment case
  • WHO Foundation
• Accountability »
  • Audit
  • Programme Budget
  • Financial statements
  • Programme Budget Portal
  • Results Report
• Governance »
  • World Health Assembly
  • Executive Board
  • Election of Director-General
  • Governing Bodies website
  • Member States Portal
• Home/
• Health topics/
• Malaria

WHO/G. Tapper

A woman walks with her child in the village of Kingombe, near Kalemie, in the Democratic Republic of the Congo.

©
Credits

Fact sheets

Questions and answers

• Malaria
• Malaria & COVID-19
• Malaria vaccine
• Artemisinin resistance

Databases and tools

• Malaria Threats Map
• Countries and territories certified malaria-free by WHO
• Global Health Observatory

Initiatives and groups

• Malaria Mekong Elimination Programme
• Malaria Vaccine Implementation Programme

Resolutions and decisions

Technical work

• Global Malaria Programme

News

All →

Time to deliver zero malaria: invest, innovate, implement

Visit the campaign page

Latest publications

All →

Between January and March 2023, Greater Mekong subregion (GMS) countries reported 2877 malaria cases.

In 2021, preliminary results of observational studies from the Community Access to Rectal Artesunate for Malaria (CARAMAL) project did not confirm the. ..

WHO has recommended rectal artesunate (RAS) as an effective pre-referral treatment for severe malaria since 2006. On 18-19 October 2022, WHO convened a…

A WHO meeting on the regional response to the invasion of Anopheles stephensi in Africa was held in Addis Ababa, Ethiopia on 8–10 March 2023. This…

Our work

Feature stories

All →

Infographics

All →

Videos

All →

6 July 2023

The spread of Anopheles stephensi in Africa

6 July 2023

WHO recommendations on new types of insecticide-treated nets

6 July 2023

Malaria response in urban areas

25 April 2023

Malaria: the real-world impact of the first malaria vaccine in Kenya

Related heath topics

Related campaigns

World Immunization Week

A 4-Day Incubation Period of Plasmodium falciparum Infection in a Nonimmune Patient in Ghana: A Case Report

• Journal List
• Open Forum Infect Dis
• PMC6335624

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
the contents by NLM or the National Institutes of Health.

Learn more about our disclaimer.

Open Forum Infect Dis. 2019 Jan; 6(1): ofy169.

Published online 2019 Jan 17. doi: 10.1093/ofid/ofy169

,¹,^2,3,⁴,⁴,⁴ and ^5,6

Author information Article notes Copyright and License information Disclaimer

Plasmodium falciparum can cause severe infection and has the shortest incubation period compared with all the other Plasmodium species. Incubation periods of 9–14 days for the immune and 6–14 days for the nonimmune have been reported for P. falciparum. However, an incubation period of less than 5 days has not been reported, as of yet. This report presents a case of a 23-year-old nonimmune female who presented with signs and symptoms 4 days after being bitten by mosquitoes while visiting Ghana. The patient was successfully treated with a 1-day course of parenteral artesunate, followed by a 3-day course of oral artemisinin combination therapy.

Keywords: artesunate, Ghana, incubation period, Malaria, nonimmune, Plasmodium falciparum, West Africa

Plasmodium falciparum is one of the prominent Plasmodium species, transmitted by malaria-causing vectors, in Ghana [1, 2]. This Plasmodium species is responsible for the majority of the uncomplicated and severe malaria cases that are reported in clinics and hospitals throughout Ghana [3]. Among the 5 species of Plasmodium that cause human infection, P. falciparum causes the most severe form of malaria [4]. Like the other species, P. falciparum is transmitted by the bite of an infected female Anopheles mosquito; however, it has a relatively shorter incubation period than the others [5]. The incubation period for P. falciparum is 9–14 days, whereas those of P. vivax and P. malariae are 12–17 days and 18–40 days, respectively [5]. Though a shorter incubation period of 6 days for P. falciparum has been reported, especially in the nonimmune [4], an incubation period of less than 5 days has not been reported in literature. Presented here is a case of a 4-day incubation period of P. falciparum infection in a nonimmune patient in Ghana.

A 23-year-old female medical student from the United Kingdom presented to a local hospital 5 days after arriving in Ghana, with a 24-hour history of fever, chills, bodily pains, vomiting, and diarrhea. She reported a recent incident of several mosquito bites while she was sitting outside the first night she arrived in the country. The patient had never visited Africa before this trip. She had been taking 250 mg of mefloquine once a week for malaria prophylaxis but admitted to not being compliant with her medication. The patient admitted to being a cigarette smoker and to smoking about 3 packs per week. Since the onset of her symptoms, she had vomited twice and passed loose, nonbloody stool 4 times. Upon examination, the patient exhibited several insect bite marks bilaterally on the legs and a temperature of 37.8°C; she was not dehydrated, pale, or in respiratory distress. She had a flat abdomen but reported mild epigastric tenderness. Breath sounds were clear bilaterally; in addition, heart sounds were clear, with no rubs, murmurs, or gallops. The patient was conscious and oriented to time, place, and person. Her full blood count investigation revealed a hemoglobin level (Hb) of 12.3 g/dL; white blood cell count (WBC) of 8.2 × 10⁹ µL with differentials (neutrophils 50%, lymphocytes 30%, monocytes 20%, and basophils 0%) and platelets of 158 × 10⁹ uL. A rapid diagnostic test (RDT) was positive for malaria parasites, and malaria parasites were also seen on blood film microscopy, with a parasitemia level of 2+. Urine pregnancy test was negative, and urinalysis showed no signs of infection. The patient was diagnosed with malaria and was immediately started on artesunate injection, 160 mg Q12H. The patient was also placed on 500 mL 5% dextrose normal saline infusion, alternating with 500 mL ringers lactate infusion, for 24 hours. The patient’s fever, vomiting, and diarrhea subsided 24 hours after commencing treatment. The patient was subsequently placed on oral, adult-course artemether lumefantrine (80/480 mg, repeated every 8 hours for the first day, then twice daily for the next 2 days) and paracetamol (acetaminophen) 1 g every 8 hours for 3 days. The patient’s condition improved, and she was discharged 3 days after. The patient was re-examined a week later and found to be recovering well, with resolution of her symptoms. Before leaving Ghana, 6 weeks post–hospital admission, there was no parasite observed in her blood film microscopy, and RDT was negative.

Our patient had not visited Africa or any other malaria-endemic region of the world. Therefore, she had no form of immunity against malaria. She manifested febrile symptoms 4 days after the mosquito bites, which infected her with the malaria parasite, as evidenced by the positive P. falciparum–specific RDT.

The virulence of P. falciparum is seen in the severity of the disease [4, 6]. It has also been reported to have a short incubation period and life cycle [4, 6]. The life cycle begins with the bite from an infected female Anopheles mosquito. The sporozoites’ journey through the liver to the red blood cells which is marked by 2 important periods in the life cycle: the prepatent period (from sporozoite entry to parasite detection in the blood) and the incubation period (sporozoites to the manifestation of symptoms) [4]. The duration of these periods, especially the incubation period, is usually influenced by the level of immunity of the infected patient, antimalarial prophylaxis, and previous malaria treatment [4, 7]. The nonimmune state of our patient would have been responsible for the unusually short incubation period noted in this case [4]. Though she was on mefloquine prophylaxis, which is specific to P. falciparum [8], she was not consistent in taking the course. Though the patient had a short incubation period, her symptoms were not severe, probably because she reported to the hospital as soon as the symptoms began. She presented with the typical malarial symptoms of fever, chills, vomiting, and diarrhea [9]. The physical findings were also not remarkable, which is not uncommon, even in nonimmune patients [4]. The laboratory results also reflect the unremarkable nature of this infection, as all blood cells (leukocytes, red cells, and platelets) were within normal reference range. Usually, more severe infections, especially in the nonimmune, present with thrombocytopenia, anemia, and neutrophilia with band formation [10]. RDT was used as a diagnostic tool to diagnose malaria in this patient, and the positive RDT was confirmed with microscopy, which is indeed the best practice in laboratory diagnosis of malaria [11–13]. Though the patient did not present with severe malaria and, as per the World Health Organization guidelines, being nonimmune is not a criterion for treatment with intravenous artesunate [14], the decision to start the patient on parenteral antimalarial was because of the vomiting, as she might not have been able to tolerate oral medication. Artesunate was the parenteral antimalarial drug of choice for this patient. It is a very efficacious drug, whose rapid parasite clearance, lack of or minimal clinical side effects, and an easy administration made it a better option than quinine [15, 16].

P. falciparum malaria typically manifests within 2 months of exposure to mosquito bites and generally presents clinically in travelers after their return from an endemic region [17]. Unlike the typical incubation period, this case highlights the successful management of P. falciparum infection occurring in a nonimmune patient 4 days after being bitten by mosquitoes. The patient was successfully treated with a 1-day course of parenteral artesunate, followed by a 3-day course of oral antimalarial artemisinin combination therapy.

Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

1.
Malaria, D. F. I. D. Country Profiles. 2011. Available at: https://www.unicef.org/health/files/Annual-report-accounts-2011-12.pdf

2.
Owusu EDA, Brown CA, Grobusch MP, Mens P.
Prevalence of Plasmodium falciparum and non-P. falciparum infections in a highland district in Ghana, and the influence of HIV and sickle cell disease. Malar J 2017; 16:167. [PMC free article] [PubMed] [Google Scholar]

3.
World Health Organization. World Malaria Report 2015. Geneva, Switzerland: WHO Press, World Health Organization; 2015. [Google Scholar]

4.
Trampuz A, Jereb M, Muzlovic I, Prabhu RM.
Clinical review: severe malaria. Crit Care 2003; 7:315–23. [PMC free article] [PubMed] [Google Scholar]

5.
Brasil P, de Pina Costa A, Pedro RS, et al..
Unexpectedly long incubation period of Plasmodium vivax malaria, in the absence of chemoprophylaxis, in patients diagnosed outside the transmission area in Brazil. Malar J 2011; 10:122. [PMC free article] [PubMed] [Google Scholar]

6.
Hayward RE, Tiwari B, Piper KP, et al..
Virulence and transmission success of the malarial parasite Plasmodium falciparum. Proc Natl Acad Sci U S A 1999; 96:4563–68. [PMC free article] [PubMed] [Google Scholar]

7.
Taylor TE, Strickland GT..
Malaria in Hunter’s Tropical Strickland, GT. Hunter’s Tropical Medicine and Emerging Infectious Diseases, Ed. 8. Philadelphia, PA: WB Saunders; 2000. ISBN: 0721662234; Record Number: 20013047493. [Google Scholar]

8.
Schwartz E.
Prophylaxis of malaria. Mediterr J Hematol Infect Dis 2012; 4:e2012045. [PMC free article] [PubMed] [Google Scholar]

9.
Genton B, D’Acremont V.
Clinical features of malaria in returning travelers and migrants. In: Schlagenhauf P, ed. Travelers’ Malaria. Hamilton, Ontario: BC Decker Inc; 2001:371–92. [Google Scholar]

10.
D’Acremont V, Landry P, Mueller I, et al..
Clinical and laboratory predictors of imported malaria in an outpatient setting: an aid to medical decision making in returning travelers with fever. Am J Trop Med Hyg 2002; 66:481–6. [PubMed] [Google Scholar]

11.
Lee SH, Kara UA, Koay E, et al..
New strategies for the diagnosis and screening of malaria. Int J Hematol 2002; 76:291–3. [PubMed] [Google Scholar]

12.
Endeshaw T, Gebre T, Ngondi J, et al..
Evaluation of light microscopy and rapid diagnostic test for the detection of malaria under operational field conditions: a household survey in Ethiopia. Malar J 2008; 7:118. [PMC free article] [PubMed] [Google Scholar]

13.
Tangpukdee N, Duangdee C, Wilairatana P, Krudsood S.
Malaria diagnosis: a brief review. Korean J Parasitol 2009; 47:93–102. [PMC free article] [PubMed] [Google Scholar]

14.
World Health Organization. Guidelines for the Treatment of Malaria. Geneva, Switzerland: WHO Press, World Health Organization; 2015. [Google Scholar]

15.
Day N, Dondorp AM.
The management of patients with severe malaria. Am J Trop Med Hyg 2007; 77:29–35. [PubMed] [Google Scholar]

16.
Zoller T, Junghanss T, Kapaun A, et al..
Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis 2011; 17:771–7. [PMC free article] [PubMed] [Google Scholar]

17.
Dauby N, Figueiredo Ferreira M, Konopnicki D, et al..
Case report: delayed or recurrent Plasmodium falciparum malaria in migrants: a report of three cases with a literature review. Am J Trop Med Hyg 2018; 98:1102–6. [PMC free article] [PubMed] [Google Scholar]

---

Articles from Open Forum Infectious Diseases are provided here courtesy of Oxford University Press

---

What you need to know about malaria

Ministry of Health of the Astrakhan Region

Center for Medical Prevention

Memo for the population.

WHAT YOU NEED TO KNOW ABOUT MALARIA!

MALARIA is a severe parasitic disease widespread in countries with a tropical and subtropical climate (Asia Minor and Southeast, Africa, South America) and neighboring countries (Azerbaijan, Armenia, Uzbekistan, Tajikistan, Georgia). Malaria is characterized by attacks of fever (fever), anemia, enlargement of the liver and spleen .

Infection occurs when bitten by malarial mosquitoes. There are 4 types of malaria: tropical, three-day, four-day and oval malaria. The most severe is the tropical form, common in African countries.

According to the World Health Organization, currently 82 countries of the world are highly endemic for malaria and are in the process of combating it, and only 16 countries have achieved the elimination of malaria in their territories through anti-epidemic (preventive) measures, and 27 countries have received the status of “malaria-free”, confirmed by the WHO certificate. Russia is represented in the group of countries directing efforts to prevent local transmission of malaria.

Malaria is transmitted from a sick person to a healthy person through the bites of female mosquitoes. In addition, there are two more ways of infection – through blood transfusion and intrauterine, when a woman with malaria infects her unborn child. Entered into the human body during the bite of malarial mosquitoes, the parasites circulate in the blood, and then are carried to the liver, in the cells of which they begin their development.

The incubation period (the period from the moment of infection to the onset of the first clinical symptoms) ranges from 7 days to 1 month (in case of a tropical form of malaria, the incubation period can last up to 3 years).

Signs of the disease – the disease begins acutely: weakness, severe headache, chills appear. Then recurring attacks of fever begin, in which the body temperature rises to 40 ° and above, and lasts for several hours. The fever is accompanied by severe chills; at the end of the attack marked sweating. Attacks are repeated regularly – after a certain time (every other day, two or three days later). When such attacks occur, you should immediately seek medical help.

Tropical malaria the most severe form of malaria. The incubation period most often ranges from 8 to 16 days. Headache, fatigue, nausea, loss of appetite may occur 3-4 days before the development of the first clinical signs. The initial stages of the disease are characterized by severe chills, a feeling of heat, severe headache. In the absence of timely treatment, a fatal outcome occurs. Recovery depends on the correct selection of antimalarial drugs and the equipment of the clinic.

Malaria parasites are found in the blood of a sick person and can only be detected by examining the blood under a microscope. Treatment of this dangerous disease is carried out taking into account the type of pathogen and its sensitivity to chemotherapy drugs.

Prevention of malaria.

All travelers to tropical countries in Africa, Southeast Asia, Central and South America are recommended to carry out specific prophylaxis of malaria by taking antimalarial chemicals. More detailed advice on dosages and regimens for taking antimalarial drugs can be obtained from the offices of infectious diseases in polyclinics at the place of residence.

It must be remembered that during a stay in a malaria-prone country and within 3 years after returning home, in case of any increase in temperature, you should immediately contact a medical institution, informing the doctor about the fact of staying in tropical countries endemic for malaria.

In addition to taking antimalarial drugs, it is necessary to remember about personal non-specific prevention of malaria: the use of repellents (mosquito repellents), in the absence of air conditioning in places of accommodation, windows and doors should be blocked, electric fumigators should be used to kill mosquitoes.
People living in areas endemic for malaria should observe the following recommendations during their stay in the outbreak:

• dress in tight, as close as possible, light-colored clothing when leaving the house after sunset;
• apply repellents to exposed areas of the body;
• sleep in rooms that exclude the penetration of blood-sucking insects;
• before going to bed, treat the room with an insecticidal spray or use fumigators;
• in the presence of a large number of mosquitoes and the impossibility of screening the windows, organize sleep under a canopy made of gauze and treated with insecticide.

Remember! Only early detection of malaria patients will help them recover and prevent the spread of infection among the surrounding population!

Follow all the rules for malaria prevention! Take care of yourself!

The material was prepared by
editorial and publishing department
GBUZ JSC “Center for Medical Prevention”
2015.

414024, Astrakhan,
sq. Freedom / st. Kotovskogo, d.2/6,
Tel. (fax) 8 (8512) 51-24-77,
e-mail: This email address is being protected from spambots. You must have JavaScript enabled to view.

Malaria and its prevention | Federal Budgetary Institution “Rostov Research Institute of Microbiology and Parasitology” of Rospotrebnadzor

Malaria and its prevention

Malaria (swamp fever, intermittent fever) is an acute infectious disease, which is characterized by the defeat of red blood cells by protozoan intracellular parasites of the genus Plasmodium (malarial plasmodium). It is transmitted through the bites of malarial mosquitoes of the genus Anopheles, through blood transfusions, or from mother to fetus during pregnancy. One bite of an infected mosquito is enough for a portion of sporozoites (spores) of the causative agent of malaria to enter the human blood or lymph along with its saliva. Next comes the complex life cycle of the malaria pathogen in the human body, the result of which is the manifestation of malaria in humans. At the same time, the blood of a person who has malaria becomes dangerous. A blood transfusion can cause infection in other people, or another mosquito can become infected when bitten.

How does malaria manifest itself?

Depending on the type of malaria pathogen, a person becomes infected with one of 4 forms of malaria – three-day malaria, four-day malaria, tropical and oval malaria. The most dangerous, which can lead to severe complications and death, is tropical malaria. The incubation period (from the moment of the bite to the first signs of the disease) – with tropical malaria is from 7 to 30 days, with other forms up to 14 months. After this, acute attacks of fever (primary attack) appear, which are replaced by a fever-free period. The number of attacks in primary malaria reaches 8-12. Then, in some cases, recovery occurs, but more often the disease again makes itself felt.

A malarial attack consists of two phases – chills and sweating. The chill phase can last from several minutes to several hours, the body temperature during this period reaches 39-40 ° C and above, the skin acquires a pale or pale blue color, becomes cold, covered with pimples. During this phase, the patient suffers from a severe headache, increasing muscle pain, vomiting, thirst, and sometimes confusion and delirium. The growing heat causes a sharp reddening of the skin of the face, an accelerated heartbeat. After the end of this phase, there is a sharp sweating, while the body temperature drops below normal. The patient’s condition improves, only weakness remains. After a while, the attacks are repeated.

Immunity after malaria is formed slowly and almost does not protect against re-infection. However, with re-infection, the disease is less severe.

The diagnosis is made on the basis of laboratory tests and the detection of typical signs.

Epidemiology of malaria

As a result of the huge complex work, by 1960 malaria was practically eliminated in the USSR, but in the 70-80s, due to the expansion of interstate ties with the countries of Africa, Southeast Asia, and Latin America, a tendency towards an increase in the incidence of imported malaria began to be observed. There is a real threat of resumption of the transmission of this infection in the south of Russia, in the Volga region and other regions. The potential for malaria to spread is determined by the length of the mosquito transmission season.

Malaria occurs seasonally: in a temperate climate for 1.5-3 months, in subtropical regions -5-8 months, in the tropics – all year round.

How real is the threat of malaria within our country? Indeed, we do not seem to have typical malarial conditions – heat and tropical swamps. But recent active human movements from north to south and back, tourist visits to the countries of Asia, Africa, Latin America can open a new chapter in the history of Russian malaria, especially since the climatic conditions in Russia do not prevent mosquitoes from living in our open spaces – anopheles carriers of malaria pathogens.

Malaria prevention

There are currently no vaccines against malaria. The main preventive measure is protection from mosquito bites. Therefore, the fight against malaria requires the active participation of each person. You need to make sure that open water does not stagnate near the house, protect your home by netting door and window openings with mosquito nets, preferably with special repellent impregnation (chemicals that repel mosquitoes). In areas dangerous for malaria (southern regions), it is better to be dressed and shod in light clothes at night. Clothing should be spacious with long sleeves, instead of shorts – trousers, instead of sandals – sneakers with socks.

The following repellents are used to protect against mosquitoes: Komarex, Biban, DEFI-plus, Evital, Taiga, Defizol, Arodet, Komarant, Defizol-2, etc.

Electrofumigators, mosquito coils, sprayers (aerosols) are used to treat the interior. Folk remedies that repel mosquitoes: the smells of cloves, eucalyptus, basil, anise – are used in the form of oils for application to the skin or adding a drop of oil to a fire source (fireplace, stove, fire, frying pan). In addition, you can use chamomile bouquets that will repel mosquitoes for 5-7 days. In a tablespoon of any cologne, you can add 8-10 drops of these oils and wipe the exposed areas of the body. To relieve itching after mosquito bites, you can use crushed leaves of bird cherry, mint, parsley, plantain, garlic clove, dandelion juice, green onion, soda solution (1 teaspoon of baking soda or ammonia in a glass of water), Vietnamese Asterisk balm.

Need to know!

• – Everyone traveling to countries with a tropical and subtropical climate is obliged to consult with a local doctor about the danger of contracting malaria, the need to take antimalarial drugs and the absence of contraindications to this group of drugs.
• – The use of drugs should be started one to two weeks before the onset of the possibility of infection, continue the entire period of risk and 4 weeks after its termination.
• – If you have malaria, you must follow all the doctor’s prescriptions.